{"id":"W2602047891","doi":"10.1200/jco.2017.35.15_suppl.4514","title":"Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ozmosis Research (Canada); Queen Elizabeth II Health Sciences Centre; Juravinski Cancer Centre; McMaster University; London Health Sciences Centre; BC Cancer Agency; Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal; Regional Municipality of Durham; CancerCare Manitoba; University Health Network; Ottawa Regional Cancer Foundation; Sunnybrook Hospital","funders":"","keywords":"Medicine; Toxicity; Clinical endpoint; Dosing; Internal medicine; Sunitinib; Phases of clinical research; Urology; Gastroenterology; Cancer; Surgery; Clinical trial; Oncology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001954691,0.001578627,0.002716989,0.0005923228,0.0004162835,0.0007322325,0.000925388,0.00110089,0.005495033],"category_scores_gemma":[0.0007432487,0.0007446035,0.001041504,0.0004739632,0.0008127607,0.0005362084,0.0004171885,0.002419437,0.000957019],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009540988,"about_ca_system_score_gemma":0.002190377,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001258713,"about_ca_topic_score_gemma":0.00321561,"domain_scores_codex":[0.999438,0.0002648717,0.00002856558,0.00009843775,0.00005764202,0.0001124286],"domain_scores_gemma":[0.999225,0.00009541492,0.0001278436,0.00007548287,0.0000405776,0.0004356484],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6967357,0.1361223,0.01273974,0.001153556,0.001663382,0.0002629725,0.000281567,0.004323977,0.04294495,0.0002825444,0.004391042,0.09909821],"study_design_scores_gemma":[0.5781762,0.400771,0.01405482,0.00002185955,0.0004288029,0.0002247498,0.00002605557,0.001220682,0.003533728,0.00009757862,0.001429188,0.00001542743],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9911692,0.001328769,0.0006462087,0.0002455262,0.00008563974,0.004127707,0.001087419,0.0001301732,0.001179319],"genre_scores_gemma":[0.985997,0.0009038214,0.002535013,0.0005395595,0.00012051,0.004194601,0.00293929,0.00003578817,0.002734429],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005495033,"threshold_uncertainty_score":0.01838273,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3432465780227212,"score_gpt":0.5581823151220743,"score_spread":0.2149357370993531,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}